248 related articles for article (PubMed ID: 27457469)
1. Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.
Kawase K; Vittitow JL; Weinreb RN; Araie M;
Adv Ther; 2016 Sep; 33(9):1612-27. PubMed ID: 27457469
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects.
Araie M; Sforzolini BS; Vittitow J; Weinreb RN
Adv Ther; 2015 Nov; 32(11):1128-39. PubMed ID: 26563323
[TBL] [Abstract][Full Text] [Related]
3. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
[TBL] [Abstract][Full Text] [Related]
4. Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings.
Weinreb RN; Liebmann JM; Martin KR; Kaufman PL; Vittitow JL
J Glaucoma; 2018 Jan; 27(1):7-15. PubMed ID: 29194198
[TBL] [Abstract][Full Text] [Related]
5. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study.
Weinreb RN; Ong T; Scassellati Sforzolini B; Vittitow JL; Singh K; Kaufman PL;
Br J Ophthalmol; 2015 Jun; 99(6):738-45. PubMed ID: 25488946
[TBL] [Abstract][Full Text] [Related]
6. Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.
Hoy SM
Drugs; 2018 May; 78(7):773-780. PubMed ID: 29761382
[TBL] [Abstract][Full Text] [Related]
7. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
Asrani S; Bacharach J; Holland E; McKee H; Sheng H; Lewis RA; Kopczynski CC; Heah T
Adv Ther; 2020 Apr; 37(4):1620-1631. PubMed ID: 32166538
[TBL] [Abstract][Full Text] [Related]
8. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension.
Fingeret M; Gaddie IB; Bloomenstein M
Clin Exp Optom; 2019 Nov; 102(6):541-550. PubMed ID: 30614563
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study.
Medeiros FA; Martin KR; Peace J; Scassellati Sforzolini B; Vittitow JL; Weinreb RN
Am J Ophthalmol; 2016 Aug; 168():250-259. PubMed ID: 27210275
[TBL] [Abstract][Full Text] [Related]
10. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
[TBL] [Abstract][Full Text] [Related]
11. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.
Kaufman PL
Expert Opin Pharmacother; 2017 Mar; 18(4):433-444. PubMed ID: 28234563
[TBL] [Abstract][Full Text] [Related]
12. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
Ge J; Li X; Sun X; He X; Zhang H
Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
[TBL] [Abstract][Full Text] [Related]
13. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of dorzolamide–timolol (COSOPT) in patients who were treatment naive for open-angle glaucoma or ocular hypertension: the COSOPT first-line study.
Crichton AC; Harasymowycz P; Hutnik CM; Behki R; Boucher S; Ibrahim F; Rifkind AW; Solomon L; Liao C; Bastien NR; Sampalis JS
J Ocul Pharmacol Ther; 2010 Oct; 26(5):503-11. PubMed ID: 20874498
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours.
Liu JHK; Slight JR; Vittitow JL; Scassellati Sforzolini B; Weinreb RN
Am J Ophthalmol; 2016 Sep; 169():249-257. PubMed ID: 27457257
[TBL] [Abstract][Full Text] [Related]
16. Fixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study.
Nakano T; Mizoue S; Fuse N; Iwase A; Matsumoto S; Yoshikawa K
Adv Ther; 2015 Sep; 32(9):823-37. PubMed ID: 26424331
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of first- or second-line latanoprost on intraocular pressure and ocular symptoms in patients with open-angle glaucoma or ocular hypertension].
Baudouin C; Rouland JF; Nordmann JP; Bron A; Pelen F
J Fr Ophtalmol; 2006 Jun; 29(6):615-24. PubMed ID: 16885890
[TBL] [Abstract][Full Text] [Related]
18. First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure.
Denis P; Baudouin C; Bron A; Nordmann JP; Renard JP; Rouland JF; Sellem E; Amrane M
BMC Ophthalmol; 2010 Feb; 10():4. PubMed ID: 20181282
[TBL] [Abstract][Full Text] [Related]
19. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
[TBL] [Abstract][Full Text] [Related]
20. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]